AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Targeted Delivery to the Heart Endothelium

Technology Benefits

No other methods exist currently to deliver drugs or genes specifically to the heart endothelium

Technology Application

Targeted drug delivery vehicles Contrast agents for imaging

Detailed Technology Description

Ligand-targeted liposomes are increasingly being recognized as an effective strategy to deliver drugs to specific organs; however, few studies have quantified endothelial binding of targeted liposomes. Researchers at the University of California, Davis have discovered that embedding high concentrations of short, linear, arginine-terminated peptides into nanoparticles allows for concentrated binding of the particles selectively to heart endothelium and the vascular endothelium in the heart.

Supplementary Information

Patent Number: US8506928B2
Application Number: US2008206569A
Inventor: Ferrara, Katherine | Zhang, Hua | Kusunose, Jiro
Priority Date: 7 Sep 2007
Priority Number: US8506928B2
Application Date: 8 Sep 2008
Publication Date: 13 Aug 2013
IPC Current: A61K005100 | A61M003614
US Class: 42400169 | 42400111 | 42400165 | 42400181 | 42400185 | 42400189
Assignee Applicant: The Regents of the University of California
Title: Methods and compounds for targeting tissues
Usefulness: Methods and compounds for targeting tissues
Summary: The composition is useful for delivering therapeutic agent e.g. amnioterone or digoxin, or imaging agent e.g. radiolabel, such as [ 18 F], [ 18 F]FDP or 64Cu, preferably [ 18 F]FDP or dye to a cell e.g. mammalian cell, human cell, cardiac cell, endothelial cell, cardiac endothelial cell, human coronary artery endothelial cell (HCAEC), human umbilical vein endothelial cells (HUVEC), brain cell or cancer cell, preferably cardiac endothelial cell for positron emission tomography (PET) imaging by administering the composition (all claimed), and for treating and/or diagnosing diseases such as cardiovascular diseases.
Novelty: Composition for delivering compound e.g. therapeutic agent or imaging agent to cell e.g. human cell for diagnosing or treating diseases e.g. cardiovascular disease, comprises peptide, particle for carrying compound, and linking molecule